Combination peroxisome proliferator-activated receptor γ and α agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content

Diabetic Medicine

Volumn 27, Issue 2, 2010, Pages 150-156

  Balasubramanian, R ^a   Gerrard, J ^a   Dalla Man, C ^b   Firbank, M J ^a   Lane, A ^a   English, P T ^c   Cobelli, C ^b   Taylor, Roy ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF PADOVA   (Italy)

^c NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Endogenous glucose production; Liver fat; Magnetic resonance spectroscopy; PPAR ; PPAR

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BEZAFIBRATE; C PEPTIDE; FATTY ACID; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ABDOMINAL FAT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DIET RESTRICTION; DRUG EFFECT; DRUG POTENTIATION; FAT CONTENT; FATTY ACID BLOOD LEVEL; FEMALE; GLUCAGON BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE OXIDATION; HUMAN; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIVER; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PROTEIN BLOOD LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; ABDOMINAL WALL MUSCULATURE; AGONISTS; BLOOD; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ABDOMINAL MUSCLES; ADULT; AGED; BEZAFIBRATE; BLOOD GLUCOSE; BODY WEIGHT; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; GLUCAGON; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIVER; MIDDLE AGED; PPAR ALPHA; PPAR GAMMA; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 76249091001     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2009.02906.x     Document Type: Article

References (30)

1. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000 106 : 171 176.
2. Ravikumar B, Gerrard J, Dalla Man C, Firbank MJ, Lane A, English PT et al. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content. Diabetes 2008 57 : 2288 2295.
3. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003 52 : 1364 1370.
4. Teranishi T, Ohara T, Maeda K, Zenibayashi M, Kouyama K, Hirota Y et al. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus. Metabolism 2007 56 : 1418 1424.
5. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes 2001 50 : 411 417.
6. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B et al. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 2000 275 : 16638 16642.
7. Chou CJ, Haluzik M, Gregory C, Dietz KR, Vinson C, Gavrilova O et al. WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J Biol Chem 2002 277 : 24484 24489.
8. Moller DE, Berger JP. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes Relat Metab Disord 2003 3 : S17 S21.
9. Minnich A, Tian N, Byan L, Bilder G. A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle. Am J Physiol Endocrinol Metab 2001 280 : E270 E279.
10. Kim H, Haluzik M, Asghar Z, Yau D, Joseph JW, Fernandez AM et al. Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 2003 52 : 1770 1778.
11. Fievet C, Fruchart JC, Staels B. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol 2006 6 : 606 614.
12. Cree MG, Newcomer BR, Read LK, Sheffield-Moore M, Paddon-Jones D, Chinkes D et al. Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-alpha agonist treatment. Mech Ageing Dev 2007 128 : 558 565.
13. Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 2007 50 : 1723 1731.
14. Jones IR, Swai A, Taylor R, Miller M, Laker MF, Alberti KG. Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM. Diabetes Care 1990 13 : 855 863.
15. Taniguchi A, Fukushima M, Sakai M, Tokuyama K, Nagata I, Fukunaga A et al. Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. Metabolism 2001 50 : 477 480.
16. Flory JH, Ellenberg S, Szapary PO, Strom BL, Hennessy S. Antidiabetic action of bezafibrate in a large observational database. Diabetes Care 2009 32 : 547 551.
17. Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 1983 55 : 628 634.
18. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 1959 82 : 420 430.
19. Radziuk J, Norwich KH, Vranic M. Experimental validation of measurements of glucose turnover in nonsteady state. Am J Physiol 1978 234 : E84 E93.
20. Thomas EL, Saeed N, Hajnal JV, Brynes A, Goldstone AP, Frost G et al. Magnetic resonance imaging of total body fat. J Appl Physiol 1998 85 : 1778 1785.
21. Bell DS, Ovalle F. Troglitazone interferes with gemfibrozil's lipid-lowering action. Diabetes Care 1998 21 : 2028 2029.
22. Boden G, Homko C, Mozzoli M, Zhang M, Kresge K, Cheung P. Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention. Diabetes 2007 56 : 248 255.
23. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I et al. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004 109 : 2197 2202.
24. Tenenbaum A, Motro M, Fisman EZ, Adler Y, Shemesh J, Tanne D et al. Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J 2005 26 : 2032 2038.
25. Nakamuta M, Morizono S, Soejima Y, Yoshizumi T, Aishima S, Takasugi S et al. Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation. Transplantation 2005 15 : 608 612.
26. Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: The bezafibrate lessons. Cardiovasc Diabetol 2005 4 : 14.
27. Hertz R, Arnon J, Bar-Tana J. The effect of bezafibrate and long-chain fatty acids on peroxisomal activities in cultured rat hepatocytes. Biochim Biophys Acta 1985 836 : 192 200.
28. Waterman IJ, Zammit VA. Differential effects of fenofibrate or simvastatin treatment of rats on hepatic microsomal overt and latent diacylglycerol acyltransferase activities. Diabetes 2003 51 : 1708 1713.
29. Edvardsson U, Ljungberg A, Linden D, William-Olsson L, Peilot-Sjogren H, Ahnmark A et al. PPARalpha activation increases triglyceride mass and adipose differentiation-related protein in hepatocytes. J Lipid Res 2006 47 : 329 340.
30. Fonesca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 2003 115 : 42S 48S.